Molecular Partners AG (XSWX:MOLN) Total Assets : CHF185.61 Mil (As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Molecular Partners AG Total Assets?

Molecular Partners AG's Total Assets for the quarter that ended in Mar. 2024 was CHF185.61 Mil.

During the past 12 months, Molecular Partners AG's average Total Assets Growth Rate was -5.70% per year. During the past 3 years, the average Total Assets Growth Rate was -6.10% per year. During the past 5 years, the average Total Assets Growth Rate was -15.80% per year. During the past 10 years, the average Total Assets Growth Rate was 12.40% per year.

During the past 11 years, Molecular Partners AG's highest 3-Year average Total Assets Growth Rate was 141.20%. The lowest was -34.80%. And the median was 1.95%.

Total Assets is connected with ROA %. Molecular Partners AG's annualized ROA % for the quarter that ended in Mar. 2024 was -23.60%. Total Assets is also linked to Revenue through Asset Turnover. Molecular Partners AG's Asset Turnover for the quarter that ended in Mar. 2024 was 0.01.

Molecular Partners AG Total Assets Historical Data

The historical data trend for Molecular Partners AG's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Molecular Partners AG Total Assets Chart

Molecular Partners AG Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Assets

Get a 7-Day Free Trial

104.94

187.55

172.67

262.26

198.35

Molecular Partners AG Quarterly Data
	Jun18	Dec18	Jun19	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Assets	Get a 7-Day Free Trial															244.53	230.49	218.12	198.35	185.61

Molecular Partners AG Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Molecular Partners AG's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Assets	=	Total Equity (A: Dec. 2023 )	+	Total Liabilities (A: Dec. 2023 )
	=	176.429	+	21.923
	=	198.35

Molecular Partners AG's Total Assets for the quarter that ended in Mar. 2024 is calculated as

Total Assets	=	Total Equity (Q: Mar. 2024 )	+	Total Liabilities (Q: Mar. 2024 )
	=	168.545	+	17.06
	=	185.61

Molecular Partners AG (XSWX:MOLN) Total Assets Explanation

Total Assets is connected with ROA %.

Molecular Partners AG's annualized ROA % for the quarter that ended in Mar. 2024 is

ROA %	=	Net Income (Q: Mar. 2024 )	/	( (Total Assets (Q: Dec. 2023 )	+	Total Assets (Q: Mar. 2024 ))	/ count )
	=	-45.3	/	( (198.352	+	185.605)	/ 2 )
	=	-45.3	/	191.9785
	=	-23.60 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Molecular Partners AG's Asset Turnover for the quarter that ended in Mar. 2024 is

	Asset Turnover
=	Revenue (Q: Mar. 2024 )	/	( (Total Assets (Q: Dec. 2023 )	+	Total Assets (Q: Mar. 2024 ))	/ count )
=	2.738	/	( (198.352	+	185.605)	/ 2 )
=	2.738	/	191.9785
=	0.01

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Molecular Partners AG Total Assets Related Terms

Thank you for viewing the detailed overview of Molecular Partners AG's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Molecular Partners AG (XSWX:MOLN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Molecular Partners AG (XSWX:MOLN) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

MOLN:USA MLLCF:USA MOLNz:UK 6ML0:Germany

Address

Wagistrasse 14, Schlieren, Zurich, CHE, 8952

Website

https://www.molecularpartners.com

Molecular Partners AG is a clinical stage biopharmaceutical company. The company focuses on the discovery, development and prospective commercialization of a new class of biopharmaceutical products. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.